GLP-1 Medications for Weight Loss: Semaglutide, Wegovy & What to Expect

The approval of semaglutide for chronic weight management marked a turning point in metabolic medicine. Clinical trials for Wegovy — the higher-dose formulation of semaglutide — demonstrated average body weight reductions of 15% to 20% over 68 weeks, outcomes that had previously required bariatric surgery to achieve. These are not modest results, and they have fundamentally changed how board-certified practitioners approach medical weight loss. At Opulent, our commitment to this space is personal: Kristal, our founder and lead practitioner, lost 60 pounds on a supervised GLP-1 protocol and built our entire weight loss program around the comprehensive, medically monitored approach that made her transformation sustainable.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring gut hormone released after eating. They work through several complementary mechanisms: slowing gastric emptying so you feel full longer, signaling the brain's satiety centers to reduce appetite and food cravings, and improving insulin sensitivity in metabolically compromised tissue. Semaglutide — marketed as Ozempic at the lower diabetic dosing and Wegovy at the higher weight-management dosing — is the most widely prescribed agent in this class. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, adds GIP receptor agonism to the GLP-1 action and has demonstrated even stronger weight reduction in early trials.

Medical Supervision Makes the Difference

GLP-1 medications purchased from unregulated online sources or administered without clinical oversight carry meaningful risk. Unsupervised dose escalation is the most common source of adverse effects, including severe nausea, vomiting, and in rare cases pancreatitis. Appropriate candidate screening requires labs and a health history to rule out contraindications. Opulent's supervised program provides a structured, safe framework from day one.

• Comprehensive initial labs including fasting glucose, HbA1c, lipid panel, thyroid function, and metabolic panel
• Baseline health assessment covering personal and family medical history with specific attention to contraindications
• Slow, evidence-based dose titration starting at the lowest effective dose to minimize side effects
• Ongoing monitoring visits and laboratory follow-up at clinically appropriate intervals
• Nutritional counseling integrated into every phase of the protocol to build habits that outlast the prescription

Combining GLP-1 with Nutritional Counseling

Research consistently shows that GLP-1 medication combined with dietary guidance and behavioral support produces significantly better long-term outcomes than medication alone. The appetite suppression created by semaglutide opens a critical window during which patients can restructure their relationship with food, build sustainable eating patterns, and establish the metabolic habits that prevent weight regain after discontinuing the medication. At Opulent, nutritional counseling is not optional — it is embedded into the protocol because medication that teaches nothing leaves patients vulnerable the moment the prescription ends. Our goal is a body composition transformation that persists for years, not a temporary number on a scale.

Am I a Candidate?

GLP-1 therapy is appropriate for a defined population based on clinical guidelines established by the FDA and major endocrinology societies. The following criteria and contraindications guide our initial assessment.

• BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or sleep apnea
• Metabolic health conditions including prediabetes, insulin resistance, or elevated cardiovascular risk factors
• Contraindications include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• Active or recent history of pancreatitis requires evaluation before initiating therapy
• Pregnancy, planned pregnancy, or breastfeeding are absolute contraindications